TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 07/07/97 AND 07/18/97—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
SIG plc, R.L. Anderson, Jr., Distribution International	97–2715	07/15/97
Leo J. Hindery, Jr., Tele-Communications, Inc., Tele-Communications, Inc.	97–2719	07/15/97
SAFECO Corporation, Lincoln National Corporation, American States Financial Corporation	97–2724	07/15/97
Commercial Union plc, Charter Oak Partners, York Holding Company	97–2729	07/15/97
Cheryl L. Thompson, Watson Electric Supply Company, Watson Electric Supply Company	97–2733	07/15/97
Bindley Western Industries, Inc., James E. Richards, Tennessee Wholesale Drug Company, Inc	97–2735	07/15/97
MasTec, Inc., Wilde Construction, Inc., Wilde Construction, Inc.	97–2737	07/15/97
Ronald A. Weinberg/Micheline Charest, Stephen T. Carson & Patricia L. Carson, Carson-Dellosa Publishing Company, Inc.; The Wild Goose	97–2738	07/15/97
Torstar Corporation (a Canadian company), Mr. Jarret Schecter, Troll Communications, LLC	97–2739	07/15/97
CRH plc, Lone Star Industries, Inc., New York Trap Rock Corporation	97–2742	07/15/97
Harrowston, Inc., Anchor Lamina Inc., Anchor Lamina Inc	97–2619	07/16/97
Genesis Health Ventures, Inc., Genesis ElderCare Corp., Genesis ElderCare Corp.		07/16/97
TPG Partners II, L.P., Genesis ElderCare Corp., Genesis ElderCare Corp.	97–2643	07/16/97
Genesis Health Ventures, Inc., Genesis ElderCare Corp., The Multicare Companies	97–2645	07/16/97
TPG Investors II, L.P., Genesis ElderCare Corporation, Genesis ElderCare Corporation	97–2653	07/16/97
Edward K. Mullen, Daniel J. Sparler, Yorktowne Paper Mills, Inc.; Yorktowne Paper Mills of	97–2676	07/16/97
Apollo Investment Fund III, L.P., Three Rivers Holding Corporation, Three Rivers Holding Corporation	97–2703	07/16/97
Cox Enterprises, Inc., H and P Radio, WBHJ, L.L.C., an Alabama Limited liability Company	97–2736	07/16/97
Cypress Merchant Banking Partners, L.P., Genesis ElderCare Corp., Genesis ElderCare Corp.	97–2644	07/10/97
USA Waste Services, Inc., David R. Kraemer, Edward Kraemer & Sons, Inc.	97–1887	07/17/97
Clear Channel Communications, Inc., Triathlon Broadcasting Company, Triathlon Broadcasting of Little Rock, Inc.,	97–1007	07/18/97
AlliedSignal Inc., Grimes Partnership, L.P., FL Aerospace Holdings Corp	97–2564	07/18/97
Intellicall, Inc., WorldCom, Inc., WorldCom, Inc.	97–2616	07/18/97
Cole National Corporation, Michael J. Rosenthal, American Vision Centers, Inc.	97–2635	07/18/97
Cole National Corporation, The Fuji Bank, Limited, American Vision Centers, Inc	97–2636	07/18/97
Wolters Kluwer, nv, The Walt Disney Company, NILS Holding Company, Inc	97–2750	07/18/97
Key Energy Group, Inc., Nabors Industries, Inc., J.W. Gibson Well Service Company	97–2755	07/18/97
ACX Technologies, Inc., Tetrafluor, Inc., Tetrafluor, Inc.	97–2759	07/18/97
Reinhold Wurth, Winston L. Adams, Adams Nut and Bolt Co	97–2760	07/18/97
NationsBank Corporation, Michael Weintraub, Gibson Security Corp	97–2761	07/18/97
Kenneth R. Thomson, Journal Printing Company of Stevens Point, Wisconsin, Journal Printing Company of Stevens		
Point, Wisconsin	97–2762	07/18/97
Carrols Holdings Corporation, Richard D. Fors, Jr., see attached list	97–2765	07/18/97
ERGON, Inc., Quaker State Corporation, Quaker State Corporation	97–2767	07/18/97
Metal Management, Inc., Albert A. Cozzi, Cozzi Iron & Metal, Inc.	97–2769	07/18/97
Albert A. Cozzi, Metal Management, Inc., Metal Management, Inc.	97–2770	07/18/97
Frank J. Cozzi, Metal Management, Inc., Cozzi Iron & Metal, Inc.	97–2771	07/18/97
Argotyche, LP, Veda International Inc., Veda International Inc.	97–2776	07/18/97
Hallmark Cards, Inc. Voting Trust dated 12/04/68, William A. DeJonge, William Arthur, Inc.	97–2777	07/18/97
Cook Inlet Region, Inc, Harry DeNardi, DeNardi Corporation; DeNardi Equipment Company	97–2779	07/18/97
Lehman Brothers Holdings Inc., Harbourton Holdings, L.P., Harbourton Mortgage Co., L.P	97–2780	07/18/97
Atlas Copco AB (jointly with) Prime Service, Inc., Robert Shanin, Norquip Rentals Corpor- artion/Assets	97–2785	07/18/97
Lawrence J. Ellison, SuperGen, Inc., SuperGen, Inc.	97–2786	07/18/97
Whitney Equity Partners, L.P., Lyonnaise des Eaux, Aqua-Chem. Inc	97–2787	07/18/97
Bruckmann, Rosser, Sherrill & Co., L.P., PepsiCo, Inc., California Pizza Kitchen, Inc.	97–2788	07/18/97
American Radio Systems Corporation, Amaturo Group of California, Ltd., Amaturo Group of California, Ltd	97–2794	07/18/97
LP	97–2815	07/18/97

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202) 326–3100.

By Direction of the Commission.

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 97–19898 Filed 7–28–97; 8:45 am] BILLING CODE 6750–01–M

FEDERAL TRADE COMMISSION

[Docket No. 9280]

Blue Coral, Inc.; Blue Coral-Slick 50, Inc.; Blue Coral-Slick 50, Ltd.; Analysis To Aid Public Comment

AGENCY: Federal Trade Commission. **ACTION:** Proposed consent agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the

draft amended complaint that accompanies the consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before September 29, 1997.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room 159, 6th St. and Pa. Ave., NW., Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Elaine D. Kolish, Federal Trade Commission, S–4302, 6th & Pennsylvania Ave., NW., Washington, DC 20580. (202) 326–3042. Mary K. Engle, Federal Trade Commission, S– 4302, 6th & Pennsylvania Ave., NW., Washington, DC 20580; (202) 326–3161. SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46, and Section 3.25 of the Commission's Rules of Practice (16 CFR 3.25), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on public record for a period of sixty (60) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the accompanying complaint. An electronic copy of the full text of the consent agreement package can be obtained from the Commission Actions section of the FTC Home Page (for July 24, 1997), on the World Wide Web, at "http:// www.ftc.gov/os/actions/htm." A paper copy can be obtained from the FTC Public Reference Room, Room H-130, Sixth Street and Pennsylvania Avenue, NW., Washington, DC 20580, either in person or by calling (202) 326–3627. Public comment is invited. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with Section 4.9(b)(6)(ii) of the Commission's Rules of Practice (16 CFR 4.9(b)(6)(ii))

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission has accepted an agreement to a proposed consent order from Blue Coral, Inc.; Blue Coral-Slick 50, Inc.; and Blue Coral-Slick 50, Ltd. These three entities are successors in interest to Quaker State—Slick 50, Inc.; Slick 50 Management, Inc.; Slick 50 Products Corp.; and Slick 50 Corp. (all entities collectively, "respondents").

The proposed consent order has been placed on the public record for sixty (60) days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After sixty (60) days, the Commission will again review the agreement and the comments received and will decide whether it should withdraw from the agreement or make final the agreement's proposed order.

This matter involves allegedly deceptive representations for Slick 50 engine treatment, and aftermarket motor oil additive containing particles of the polymer polytetrafluoroethylene ("PTFE"). The Commission issued a complaint on July 12, 1996, charging that advertisements for Slick 50

disseminated by the respondents made various false and unsubstantiated claims. The Commission's complaint was withdrawn from adjudication on May 12, 1997, prior to commencement of the administrative hearing, so that the Commission could consider the proposed order.

According to the FTC complaint, the respondents falsely claimed: (1) Automobile engines generally have little or no protection from wear at or just after start-up unless they have been treated with Slick 50; (2) Automobile engines commonly experience premature failure caused by wear unless they are treated with Slick 50; (3) Slick 50 coats engine parts with a layer of PTFE; and (4) Slick 50 meets military specifications for aftermarket motor oil additives. The complaint alleged the following claims as unsubstantiated: (1) Compared to motor oil alone, Slick 50: reduces engine wear, reduces engine wear by more than 50%, reduces engine wear by up to 50%, reduces engine wear at start-up, extends the duration of engine life, lowers engine temperatures, reduces toxic emissions, increases gas mileage, and increases horsepower; (2) One treatment of Slick 50 continues to reduce engine wear for 50,000 miles; and (3) Slick 50 has been used in a significant number of U.S. Government vehicles. Lastly, the complaint alleged that respondents falsely represented: (1) Tests prove that, compared to motor oil alone, Slick 50: reduces engine wear by more than 50%, reduces engine wear by up to 50%, and reduces engine wear at start-up; and (2) Tests prove that one treatment of Slick 50 continues to reduce engine wear for 50,000 miles.

The proposed consent order contains provisions designed to prevent the respondents from engaging in similar acts and practices in the future. Part I of the proposed order prohibits the respondents from representing that: (1) Automobile engines generally have little or no protection from wear at or just after start-up unless they have been treated with Slick 50 or a similar PTFE product; (2) Automobile engines commonly experience premature failure caused by wear unless they are treated with Slick 50 or a similar PTFE product; or (3) Slick 50 or a similar PTFE product coats engine parts with a layer of PTFE.

Part II of the proposed order prohibits the respondents from misrepresenting that any oil additive or Slick 50 engine lubricating product meets the standards of any organization and from misrepresenting tests or studies when selling such products. Part II also prohibits the respondents from making any representation about the performance, benefits, efficacy,

attributes or use of such products unless, at the time they make the representation, they possess and rely upon appropriate, competent and reliable evidence that substantiates the representation.

Part III of the proposed order prohibits respondents from representing that any Slick 50 lubricating product for use in a motor vehicle, other than an engine lubricating product, reduces wear, extends the life of a part, lowers engine temperature, reduces emissions, or increases mileage or horsepower, unless, at the time they make the representation, they possess and rely upon appropriate, competent and reliable evidence that substantiates the representation.

Parts IV through IX and XI require the respondents to keep copies of advertisements making representations covered by the order; to keep records concerning those representations; including materials that they relied upon when making the representations, to notify the Commission of changes in corporate structure; to provide copies of the order to certain of respondents personnel; to send notice of the order to purchasers for resale of Slick 50; to keep records showing that the order or notice of the order was received by or sent to appropriate persons and showing any redress made available to consumers pursuant to class action lawsuits challenging conduct similar to that challenged in the Commission's complaint; to provide notice to Commission staff prior to submitting any proposed settlement of such class action lawsuits to a court; and to file with the Commission compliance reports and reports showing any redress made available to consumers pursuant to class action lawsuits. Part X provides that the order will terminate after twenty (20) years under certain circumstances.

Additionally, Paragraph 5 of the consent agreement seeks to preserve the Commission's option to seek consumer redress under Section 19 of the Federal Trade Commission Act if the respondents do not make available redress having an aggregate retail value of at least \$10 million to consumers pursuant to class action lawsuits that challenge conduct similar to that challenged in the Commission's complaint. Paragraph 5 also reserves the Commission's right to seek to intervene in any such class action lawsuit to oppose a settlement that it believes is not in the public interest.

The purpose of this analysis is to facilitate public comment on the proposed order, and it is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way their terms.

Benjamin I. Berman,

Acting Secretary.
[FR Doc. 97–19897 Filed 7–28–97; 8:45 am]
BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Public Health and Science; Federal Policies Affecting the Future of Academic Health Centers

AGENCY: Office of Public Health and Science.

ACTION: Notice of two public hearings, and comment.

SUMMARY: This notice announces that the Secretary of Health and Human Services is formally inviting public comment on issues relevant to the Department's Initiative on the Future of Academic Health Centers. The Secretary has established an interagency policy development group to review Department policies affecting academic health centers and other health professions work force issues. The policy development group will make recommendations to the Secretary for revising or implementing Federal policies that ensure that the essential public goods produced by academic health centers are maintained in the evolving health care system. These essential public goods (health professions education, biomedical and other health research, and services to vulnerable or disadvantaged individuals, as well as special services, i.e., trauma care, burn units, and transplantation units), are critical to the nation's health care system.

The policy development group of the Department's initiative is interested in gaining local and regional perspectives from across the country on the issues that surround the future of academic health centers. To gain this input, two national public hearings will be held. These hearings will focus on issues related to the future of education and research missions of academic health centers, the provision of services through academic health centers, and academic health centers' need for access to capital to achieve these missions. Individuals may provide oral comments regarding the future of academic health centers, and Federal policies affecting them. The testimony provided by key stakeholders/constituents will be considered in the development of recommendations to the Secretary. Written comments will also be accepted. DATES: Two public hearings will be held: August 25, 1997 in Houston, TX and August 27, 1997 in Chicago, IL. Requests to give oral testimony at the hearings must be received in writing by August 7, 1997. Written comments accompanying oral testimony are due August 11, 1997 for the August 25, 1997 hearing and on August 13, 1997 for the August 27, 1997 hearing. Submission deadline for written comments, without oral testimony, is August 23, 1997.

ADDRESSES: Written requests to testify and written comments on Federal policies that impact the future of academic health centers should be submitted to: Ciro V. Sumaya, M.D., M.P.H.T.M., Deputy Assistant Secretary for Health, Department of Health and Human Services, Hubert H. Humphrey Building, Room 716–G, 200 Independence Avenue, SW., Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: The office of Dr. Sumaya at the address listed above. Telephone: (202) 690–7694. Facsimile: (202) 260–4405. Electronic mail: AHCInitiative@osophs.dhhs.gov

SUPPLEMENTARY INFORMATION:

Location Information

Sammons Auditorium, Texas Medical Center Library, 1133 M.D. Anderson Boulevard, Houston, Texas, 77030 on August 25, 1997, 8:30 AM. Dirksen Building, 219 S. Dearborne Street, Courtroom #2541, Chicago, Illinois, 60604, on August 27, 1997, 8:30 AM.

Guidelines for Submitted Testimony

Those wishing to present written testimony only should accompany their testimony with an abstract that summarizes their testimony in 200 words or less.

Those wishing to present oral testimony should indicate the following in their requests: (1) which of the two public forums (Houston, Texas, August 25, 1997, or Chicago, Illinois, August 27, 1997) they would like to attend depending upon availability; (2) the type of institution or organization they represent (academic health center or school, professional association, community organization, state/local government, foundation, health plan, insurer, other provider, or other), and their mailing address, telephone number, facsimile number, and electronic mail address (if available). Written comments may be longer than the oral testimony presented. An abstract that summarizes the testimony, in 200 words or less, must accompany the written testimony.

Both of these hearings will be limited one day; therefore, it is possible that all those who wish to present oral testimony may not be accommodated. Requests for oral presentations will be honored on a first come, first serve basis. Opportunity will be provided for representation by a variety of stakeholders/constituencies, as identified above, as well as to ensure geographic distribution. Oral comments must be limited to no more than five minutes. Presenters will be notified by telephone if they will have the opportunity to provide oral testimony, with a follow-up confirmation in writing.

Testimony Content Guidelines

Both public hearings will address issues related to academic health centers' education and research missions and the provision of health care services (to under served populations, and specialized services), and related needs for access to capital to support these public missions.

Written and oral testimony prepared for these public hearings should address one or more of these questions:

Education/Work Force

What role should academic health centers play in developing the nation's health professions work force? What are the current threats and barriers to achieving those educational roles and accompanying goals?

What Federal policies are needed to improve academic health centers' capacity to produce an appropriate health professions work force at the regional, state, and national level?

Is the use of consortia (e.g., hospital networks, health professions schools) an effective means to improve health professions training and education? Are there other models? Are specific demonstrations and projects useful?

Research

What is the current status of the nation's health research enterprise (i.e., biomedical, clinical, behavioral, health services, prevention/population based research)?

What are some strategies for maintaining a strong and productive research infrastructure, including training programs, support services, and physical plants and operations?

What policies are needed to maintain and improve the nation's health research capacity and productivity?

Services

Are services to vulnerable and under served populations traditionally provided by academic health centers at